Variation in Medicaid and commercial coverage of cell and gene therapies
Growth in the availability of cell and gene therapies (CGTs) promises significant innovation in the treatment of serious diseases, but the high cost and one-time administration of CGTs has also raised concern about strain on health plan budgets and inequity in access. We used coverage information fr...
Saved in:
Main Authors: | Molly T. Beinfeld (Author), Julia A. Rucker (Author), Nola B. Jenkins (Author), Lucas A. de Breed (Author), James D. Chambers (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alcohol-Attributable Medical Costs in Commercially Insured and Medicaid Populations
by: Pelin Ozluk, PhD, et al.
Published: (2022) -
Commercial Health Plan Participation in Medicaid Managed Care: An Examination of Six Markets
by: Teresa A. Coughlin, et al.
Published: (2001) -
Associations Between Copays, Coverage Limits for Naloxone, and Prescribing in Medicaid
by: John C Messinger, et al.
Published: (2022) -
Effects of medicaid expansion on poverty disparities in health insurance coverage
by: Yilu Lin, et al.
Published: (2021) -
State Medicaid Coverage and Reimbursement of Adult Vaccines Administered by Physicians and Pharmacists
by: Julian J.Z. Polaris, JD, et al.
Published: (2024)